臨床検査57巻3号

2013年03月発行

今月の特集1 分子病理診断の進歩

K-ras

著者： 佐々木素子¹ 中沼安二¹

所属機関： ¹金沢大学大学院医薬保健研究域医学系形態機能病理学

ページ範囲：P.256 - P.261

■K-rasは代表的な癌遺伝子で，遺伝子変異による恒常的なK-ras蛋白活性化は，細胞増殖を亢進させる．

■膵癌のK-ras検査は補助診断項目として現在，保険適用になっている．

■大腸癌や肺癌では，上皮成長因子受容体（EGFR）抗体製剤の適応決定におけるEGFR発現とK-ras遺伝子変異解析が保健適用になっている．

■K-ras変異があると，EGFR抗体製剤が効かない．

参考文献

1）Schubbert S, Shannon K, Bollag G：Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer　7：295-308，2007

2）Kumar V, Abbas AK, Aster JC, eds：Robbins Basic Pathology, 9th ed, Saunders，2012

3）Porta M, Crous-Bou M, Wark PA, et al：Cigarette smoking and K-ras mutations in pancreas, lung and colorectal adenocarcinomas: etiopathogenic similarities, differences and paradoxes. Mutat Res　682：83-93，2009

4）Bosman FT, Carneiro F, Hruban RH, et al eds：WHO classification of tumours of the digestive system, IARC, Lyon，2010

5）Singh P, Srinivasan R, Wig JD：Major molecular markers in pancreatic ductal adenocarcinoma and their roles in screening, diagnosis, prognosis, and treatment. Pancreas　40：644-652，2011

6）Kanda M, Matthaei H, Wu J, et al：Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology　142：730-733，2012

7）Zaret KS, Grompe M：Generation and regeneration of cells of the liver and pancreas. Science　322：1490-1494，2008

8）Momoi H, Itoh T, Nozaki Y, et al：Microsatellite instability and alternative genetic pathway in intrahepatic cholangiocarcinoma. J Hepatol　35：235-244，2001

9）Hsu M, Sasaki M, Igarashi S, et al：KRAS and GNAS mutations and p53 overexpression in biliary intraepithelial neoplasia and intrahepatic cholangiocarcinomas. Cancer, in press

10）Mooi WJ, Peeper DS：Oncogene-induced cell senescence--halting on the road to cancer. N Engl J Med　355：1037-1046，2006

11）Varambally S, Dhanasekaran SM, Zhou M, et al：The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature　419：624-629，2002

12）Sasaki M, Yamaguchi J, Itatsu K, et al：Over-expression of polycomb group protein EZH2 relates to decreased expression of p16 INK4a in cholangiocarcinogenesis in hepatolithiasis. J Pathol　215：175-183，2008

13）日本臨床腫瘍学会KRAS遺伝子変異検討小委員会：大腸がん患者におけるKRAS遺伝子変異の測定に関するガイダンス，2009

14）van Krieken JH, Jung A, Kirchner T, et al：KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch　453：417-431，2008

15）Kamisawa T, Tsuruta K, Okamoto A, et al：Frequent and significant K-ras mutation in the pancreas, the bile duct, and the gallbladder in autoimmune pancreatitis. Pancreas　38：890-895，2009

16）Goggins M：Molecular markers of early pancreatic cancer. J Clin Oncol　23：4524-4531，2005

17）Raponi M, Winkler H, Dracopoli NC：KRAS mutation predict response to EGFR inhibitors. Curr Opin Pharmacol　8：413-418，2008

18）Lubner SJ, Mahoney MR, Kolesar JL, et al：Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. J Clin Oncol　28：3491-3497，2010